Class Action Lawsuit Filed on Behalf of Anavex Life Sciences Corp. (AVXL) Investors - Nationally Ranked Investors Rights Firm Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

ATLANTA, GA - (NewMediaWire) - March 14, 2024 - A shareholder class action lawsuit has been filed against Anavex Life Sciences Corp. (“Anavex” or the “Company”) (NASDAQ: AVXL). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information regarding the Company’s primary product, blarcamesine, its research program, the resulting data, and the methods used to analyze its studies.

If you bought Anavex shares between February 1, 2022 and January 1, 2024, and suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888)-508-6832 or, you may visit the firm’s website at www.holzerlaw.com/case/anavex/ to learn more. 

The deadline to ask the court to be appointed lead plaintiff in the case is May 13, 2024.

Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021 and 2022, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, www.holzerlaw.com, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.  

 

CONTACT:

Corey Holzer, Esq.

(888) 508-6832 (toll-free)

cholzer@holzerlaw.com

 

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.